Published in Neurol Sci on November 01, 2006
HCV-related nervous system disorders. Clin Dev Immunol (2012) 0.90
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol (2015) 0.87
Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. Medicine (Baltimore) (2013) 0.81
Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J Gastroenterol (2014) 0.78
Sicca syndrome and dementia in a patient with hepatitis C infection: a case report with unusual bifocal extrahepatic manifestations. J Maxillofac Oral Surg (2014) 0.75
Hepatitis C virus and neurological damage. World J Hepatol (2016) 0.75
fMRI resting state networks define distinct modes of long-distance interactions in the human brain. Neuroimage (2005) 8.61
Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr (2001) 2.67
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology (2011) 2.65
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology (2008) 2.37
Changes in white matter microstructure during adolescence. Neuroimage (2007) 2.22
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG (2012) 2.14
Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler (2012) 2.07
Longitudinal changes in grey and white matter during adolescence. Neuroimage (2009) 2.03
Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain (2006) 2.00
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther (2015) 1.99
Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology (2003) 1.94
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer (2006) 1.85
MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett (2000) 1.82
Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci (2006) 1.75
Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology (2010) 1.72
A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet (2001) 1.69
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain (1998) 1.68
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology (2000) 1.64
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Requests for electromyography from general practitioners and specialists: critical evaluation. Ital J Neurol Sci (1998) 1.59
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology (2009) 1.59
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet (2002) 1.56
Cerebrotendinous xanthomatosis with predominant parkinsonian syndrome: further confirmation of the clinical heterogeneity. Mov Disord (2000) 1.53
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol (2001) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. Eur J Neurol (2008) 1.44
Late diagnosis in severe and mild intellectual disability in adulthood. J Intellect Disabil Res (2004) 1.43
Cutis verticis gyrata and chromosomal fragile sites. Am J Med Genet (1991) 1.43
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42
Posterior fossa abnormalities in hereditary spastic paraparesis with spastin mutations. J Neurol Neurosurg Psychiatry (2009) 1.41
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol (2010) 1.41
Attention-deficit hyperactivity disorder: sometimes a disorder, often a clinical tautology. J Dev Behav Pediatr (1996) 1.38
Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology (2004) 1.36
The present and the future of neuroimaging in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol (2010) 1.30
A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol (1983) 1.27
Novel SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type. Neurology (2004) 1.26
Human placental neuraminidase. Activation, stabilization and association with beta-galactosidase and its protective protein. Eur J Biochem (1985) 1.23
The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer (2000) 1.22
Ataxia with vitamin E deficiency: update of molecular diagnosis. Neurol Sci (2010) 1.22
Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain (2001) 1.21
Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology (2001) 1.20
The spectrum of Notch3 mutations in 28 Italian CADASIL families. J Neurol Neurosurg Psychiatry (2005) 1.19
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology (2008) 1.19
Spectrum of clinical variability in familial deletion 22q11.2: from full manifestation to extremely mild clinical anomalies. Clin Genet (2003) 1.18
Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol (1997) 1.15
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol (2011) 1.14
Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum (2007) 1.14
Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the 'Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis (2005) 1.13
Cortical lesions in radiologically isolated syndrome. Neurology (2011) 1.12
Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat Genet (1997) 1.09
Preoperative embolization in surgical treatment of mediastinal hemangiopericytoma. Ann Thorac Surg (2000) 1.08
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol (1998) 1.08
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem (1997) 1.08
Sleep in subjects with autistic disorder: a neurophysiological and psychological study. Brain Dev (2000) 1.08
PAX6 mutation in a family with aniridia, congenital ptosis, and mental retardation. Clin Genet (2001) 1.07
Correlation dimension of EEG slow-wave activity during sleep in children and young adults. Electroencephalogr Clin Neurophysiol (1998) 1.07
Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology (2004) 1.06
Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol (2002) 1.06
Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol (2004) 1.05
MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology (2009) 1.04
Mortality of plastic-ware workers exposed to radiofrequencies. Bioelectromagnetics (1997) 1.04
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Exp Brain Res (2008) 1.04
Total parenteral nutrition-related gastroenterological complications. Dig Liver Dis (2006) 1.04
Genetic heterogeneity of megalencephalic leukoencephalopathy and subcortical cysts. Neurology (2003) 1.04
Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. Epidemiology (2001) 1.03
The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlates. Brain (1998) 1.03
Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol (2000) 1.03
Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology (2010) 1.03
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
[Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. Actas Urol Esp (2012) 1.02
Accuracy of clinical diagnostic criteria for Friedreich's ataxia. Mov Disord (2000) 1.02
Vitamin D Deficiency, hypocalcemia, and increased skeletal muscle degradation in rats. J Clin Invest (1983) 1.02
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther (2005) 1.02
MR brain imaging of fucosidosis type I. AJNR Am J Neuroradiol (2001) 1.01
Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Ann Neurol (2000) 1.01
Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Hum Mol Genet (2000) 1.01
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res (1999) 1.00
Nuclear changes in a case of X-linked Emery-Dreifuss muscular dystrophy. Muscle Nerve (1999) 1.00
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol (1997) 0.99
Mortality study of workers employed by the Italian National Institute of Health, 1960-1989. Scand J Work Environ Health (1992) 0.99
Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol (2003) 0.99